呼吸

订阅

MedSci主页 / 所有栏目 / 呼吸

长效抗体GSK3511294控制重度哮喘，III期临床试验即将开始

2021-03-18 Allan MedSci原创

重度哮喘IL-5单克隆抗体GSK3511294
关注

葛兰素史克（GSK）已开始了一项III期临床试验，以评估其长效抗IL-5单克隆抗体GSK3511294治疗严重嗜酸性粒细胞性哮喘（SEA）的能力。GSK3511294是一种研究性生物制剂，旨在通过每六

葛兰素史克（GSK）已开始了一项III期临床试验，以评估其长效抗IL-5单克隆抗体GSK3511294治疗严重嗜酸性粒细胞性哮喘（SEA）的能力。GSK3511294是一种研究性生物制剂，旨在通过每六个月一次注射对SEA患者提供长效抑制IL-5的作用。

SWIFT-2试验是III期临床计划的一部分，旨在评估GSK3511294的安全性和有效性。根据GSK的研究，IL-5是负责嗜酸性粒细胞增殖、活化和存活的关键细胞因子，它在50％以上的严重哮喘患者中发挥作用，已成为SEA的治疗靶标。

GSK高级副总裁Christopher Corsico表示：“大约有10％的哮喘患者患有严重的嗜酸性粒细胞性哮喘，这些患者可能会受益于更有针对性的疗法，以更好地控制他们的病情。我们相信，GSK3511294可以为这些患者提供另一种选择”。

哮喘是常见的气道慢性炎症疾病，主要特征是多变和复发的症状、可逆性气流阻塞，和支气管痉挛。常见症状表现为喘息、咳嗽、胸腔紧迫、胸闷和呼吸困难。普遍认为哮喘是因为基因和环境因素共同导致的。环境因素通常包含：暴露于空气污染和过敏原，其他可能的诱发因子包含阿司匹林和β受体阻断药之类的药物。

 

原始出处：

http://www.pharmatimes.com/news/gsk_launches_late-stage_study_of_long-acting_antibody_for_severe_asthma_1365462

评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1931555, encodeId=c66b193155581, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Jul 26 15:34:15 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088857, encodeId=2ccd208885ecb, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Oct 05 16:34:15 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085147, encodeId=5160208514e80, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Jul 03 03:34:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916414, encodeId=4786191641482, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jun 04 12:34:15 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653168, encodeId=c7a0165316874, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 27 04:34:15 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663686, encodeId=f35d1663686c5, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Sat Jun 05 17:34:15 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524933, encodeId=4d57152493322, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588077, encodeId=b4bb15880e770, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594871, encodeId=93c915948e188, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949374, encodeId=d3d49493e4e3, content=IL-5是负责嗜酸性粒细胞增殖、活化和存活的关键细胞因子，它在50％以上的严重哮喘患者中发挥作用，已成为SEA的治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Thu Mar 18 22:46:33 CST 2021, time=2021-03-18, status=1, ipAttribution=)]
    2021-07-26 kksonne

    #II期临床试验#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1931555, encodeId=c66b193155581, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Jul 26 15:34:15 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088857, encodeId=2ccd208885ecb, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Oct 05 16:34:15 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085147, encodeId=5160208514e80, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Jul 03 03:34:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916414, encodeId=4786191641482, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jun 04 12:34:15 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653168, encodeId=c7a0165316874, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 27 04:34:15 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663686, encodeId=f35d1663686c5, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Sat Jun 05 17:34:15 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524933, encodeId=4d57152493322, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588077, encodeId=b4bb15880e770, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594871, encodeId=93c915948e188, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949374, encodeId=d3d49493e4e3, content=IL-5是负责嗜酸性粒细胞增殖、活化和存活的关键细胞因子，它在50％以上的严重哮喘患者中发挥作用，已成为SEA的治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Thu Mar 18 22:46:33 CST 2021, time=2021-03-18, status=1, ipAttribution=)]
    2021-10-05 839640778

    #I期临床试验#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1931555, encodeId=c66b193155581, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Jul 26 15:34:15 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088857, encodeId=2ccd208885ecb, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Oct 05 16:34:15 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085147, encodeId=5160208514e80, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Jul 03 03:34:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916414, encodeId=4786191641482, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jun 04 12:34:15 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653168, encodeId=c7a0165316874, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 27 04:34:15 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663686, encodeId=f35d1663686c5, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Sat Jun 05 17:34:15 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524933, encodeId=4d57152493322, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588077, encodeId=b4bb15880e770, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594871, encodeId=93c915948e188, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949374, encodeId=d3d49493e4e3, content=IL-5是负责嗜酸性粒细胞增殖、活化和存活的关键细胞因子，它在50％以上的严重哮喘患者中发挥作用，已成为SEA的治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Thu Mar 18 22:46:33 CST 2021, time=2021-03-18, status=1, ipAttribution=)]
    2021-07-03 anminleiryan

    #GSK3#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1931555, encodeId=c66b193155581, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Jul 26 15:34:15 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088857, encodeId=2ccd208885ecb, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Oct 05 16:34:15 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085147, encodeId=5160208514e80, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Jul 03 03:34:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916414, encodeId=4786191641482, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jun 04 12:34:15 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653168, encodeId=c7a0165316874, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 27 04:34:15 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663686, encodeId=f35d1663686c5, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Sat Jun 05 17:34:15 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524933, encodeId=4d57152493322, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588077, encodeId=b4bb15880e770, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594871, encodeId=93c915948e188, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949374, encodeId=d3d49493e4e3, content=IL-5是负责嗜酸性粒细胞增殖、活化和存活的关键细胞因子，它在50％以上的严重哮喘患者中发挥作用，已成为SEA的治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Thu Mar 18 22:46:33 CST 2021, time=2021-03-18, status=1, ipAttribution=)]
    2021-06-04 juliusluan78

    #III#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1931555, encodeId=c66b193155581, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Jul 26 15:34:15 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088857, encodeId=2ccd208885ecb, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Oct 05 16:34:15 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085147, encodeId=5160208514e80, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Jul 03 03:34:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916414, encodeId=4786191641482, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jun 04 12:34:15 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653168, encodeId=c7a0165316874, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 27 04:34:15 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663686, encodeId=f35d1663686c5, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Sat Jun 05 17:34:15 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524933, encodeId=4d57152493322, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588077, encodeId=b4bb15880e770, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594871, encodeId=93c915948e188, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949374, encodeId=d3d49493e4e3, content=IL-5是负责嗜酸性粒细胞增殖、活化和存活的关键细胞因子，它在50％以上的严重哮喘患者中发挥作用，已成为SEA的治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Thu Mar 18 22:46:33 CST 2021, time=2021-03-18, status=1, ipAttribution=)]
    2021-09-27 医生2402

    #I期临床#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1931555, encodeId=c66b193155581, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Jul 26 15:34:15 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088857, encodeId=2ccd208885ecb, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Oct 05 16:34:15 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085147, encodeId=5160208514e80, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Jul 03 03:34:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916414, encodeId=4786191641482, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jun 04 12:34:15 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653168, encodeId=c7a0165316874, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 27 04:34:15 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663686, encodeId=f35d1663686c5, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Sat Jun 05 17:34:15 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524933, encodeId=4d57152493322, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588077, encodeId=b4bb15880e770, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594871, encodeId=93c915948e188, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949374, encodeId=d3d49493e4e3, content=IL-5是负责嗜酸性粒细胞增殖、活化和存活的关键细胞因子，它在50％以上的严重哮喘患者中发挥作用，已成为SEA的治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Thu Mar 18 22:46:33 CST 2021, time=2021-03-18, status=1, ipAttribution=)]
    2021-06-05 小几洁

    #重度哮喘#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1931555, encodeId=c66b193155581, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Jul 26 15:34:15 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088857, encodeId=2ccd208885ecb, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Oct 05 16:34:15 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085147, encodeId=5160208514e80, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Jul 03 03:34:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916414, encodeId=4786191641482, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jun 04 12:34:15 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653168, encodeId=c7a0165316874, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 27 04:34:15 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663686, encodeId=f35d1663686c5, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Sat Jun 05 17:34:15 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524933, encodeId=4d57152493322, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588077, encodeId=b4bb15880e770, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594871, encodeId=93c915948e188, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949374, encodeId=d3d49493e4e3, content=IL-5是负责嗜酸性粒细胞增殖、活化和存活的关键细胞因子，它在50％以上的严重哮喘患者中发挥作用，已成为SEA的治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Thu Mar 18 22:46:33 CST 2021, time=2021-03-18, status=1, ipAttribution=)]
    2021-03-20 guihongzh

    #II期临床#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1931555, encodeId=c66b193155581, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Jul 26 15:34:15 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088857, encodeId=2ccd208885ecb, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Oct 05 16:34:15 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085147, encodeId=5160208514e80, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Jul 03 03:34:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916414, encodeId=4786191641482, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jun 04 12:34:15 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653168, encodeId=c7a0165316874, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 27 04:34:15 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663686, encodeId=f35d1663686c5, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Sat Jun 05 17:34:15 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524933, encodeId=4d57152493322, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588077, encodeId=b4bb15880e770, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594871, encodeId=93c915948e188, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949374, encodeId=d3d49493e4e3, content=IL-5是负责嗜酸性粒细胞增殖、活化和存活的关键细胞因子，它在50％以上的严重哮喘患者中发挥作用，已成为SEA的治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Thu Mar 18 22:46:33 CST 2021, time=2021-03-18, status=1, ipAttribution=)]
    2021-03-20 guihongzh

    #III期临床试验#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1931555, encodeId=c66b193155581, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Jul 26 15:34:15 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088857, encodeId=2ccd208885ecb, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Oct 05 16:34:15 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085147, encodeId=5160208514e80, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Jul 03 03:34:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916414, encodeId=4786191641482, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jun 04 12:34:15 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653168, encodeId=c7a0165316874, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 27 04:34:15 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663686, encodeId=f35d1663686c5, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Sat Jun 05 17:34:15 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524933, encodeId=4d57152493322, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588077, encodeId=b4bb15880e770, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594871, encodeId=93c915948e188, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949374, encodeId=d3d49493e4e3, content=IL-5是负责嗜酸性粒细胞增殖、活化和存活的关键细胞因子，它在50％以上的严重哮喘患者中发挥作用，已成为SEA的治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Thu Mar 18 22:46:33 CST 2021, time=2021-03-18, status=1, ipAttribution=)]
    2021-03-20 智智灵药

    #III期#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1931555, encodeId=c66b193155581, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Mon Jul 26 15:34:15 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088857, encodeId=2ccd208885ecb, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Tue Oct 05 16:34:15 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085147, encodeId=5160208514e80, content=<a href='/topic/show?id=a9138292cf' target=_blank style='color:#2F92EE;'>#GSK3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8292, encryptionId=a9138292cf, topicName=GSK3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Sat Jul 03 03:34:15 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916414, encodeId=4786191641482, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Jun 04 12:34:15 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653168, encodeId=c7a0165316874, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Mon Sep 27 04:34:15 CST 2021, time=2021-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663686, encodeId=f35d1663686c5, content=<a href='/topic/show?id=ec0c95810cc' target=_blank style='color:#2F92EE;'>#重度哮喘#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95810, encryptionId=ec0c95810cc, topicName=重度哮喘)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f5b25663198, createdName=小几洁, createdTime=Sat Jun 05 17:34:15 CST 2021, time=2021-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524933, encodeId=4d57152493322, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588077, encodeId=b4bb15880e770, content=<a href='/topic/show?id=056095e171' target=_blank style='color:#2F92EE;'>#III期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9571, encryptionId=056095e171, topicName=III期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d24217580122, createdName=guihongzh, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594871, encodeId=93c915948e188, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Sat Mar 20 13:34:15 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=949374, encodeId=d3d49493e4e3, content=IL-5是负责嗜酸性粒细胞增殖、活化和存活的关键细胞因子，它在50％以上的严重哮喘患者中发挥作用，已成为SEA的治疗靶标。, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM4gCIdSaEkahCNuUWZv4iaKmqvUKHyKnBiarBM9RStQKBeV5Lh6GYYFiamdV5KlSfbLvmAgZTLtq81XA/0, createdBy=13511650672, createdName=言西早, createdTime=Thu Mar 18 22:46:33 CST 2021, time=2021-03-18, status=1, ipAttribution=)]
    2021-03-18 言西早

    IL-5是负责嗜酸性粒细胞增殖、活化和存活的关键细胞因子，它在50％以上的严重哮喘患者中发挥作用，已成为SEA的治疗靶标。

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

Am J Respir Crit Care Med：Brodalumab对中-重度哮喘无治疗作用

白介素-17(IL-17)传导通路在哮喘的发展和维持中发挥着重要的作用。以阻断人IL-17受体A(IL-17RA)介导的传导通路为目的的细胞因子靶向治疗有可能成为哮喘治疗的新方法。Brodalumab(AMG 827，美国安进公司提供)是人类抗IL-17RA免疫球蛋白（IgG2）单克隆抗体，对人类IL-17RA有高亲和力，能够阻断IL-17家族细胞因子的生物活性。为了评估Brodalumab在规范

Clin Exp Allergy：重度哮喘患者对口服泼尼松龙的反应与皮质类固醇程度有关！

由此可见，疾病严重程度并不影响全身性皮质类固醇治疗的反应。因此，这项研究并不支持重度哮喘与皮质类固醇抵抗相关的概念。只有基础嗜酸性粒细胞炎症与皮质类固醇的生理反应相关，其证实了在指导皮质类固醇治疗上测量嗜酸性粒细胞炎症的重要性。

重度哮喘的定义、评估和治疗

5月6日，我们迎来了第16个“世界哮喘日（WorldAsthmaDay，WAD）”，今年的WAD依然沿用“你可以控制你的哮喘（YouCanControlYourAsthma）”这一主题，强调了对哮喘的正确认识与积极管理。适逢欧洲呼吸学会（ERS）和美国胸科学会（ATS）联合制订的重度哮喘国际指南近期于《欧洲呼吸病学杂志》发表，下面由首都医科大学附属北京同仁医院孙永昌教授简要介绍指南内容。 定

Lancet respir med：临床3期试验：Tralokinumab，抗白介素13单克隆抗体，用于重度哮喘发作的效果和安全性评估

Tralokinumab，抗白介素-13的人类单克隆抗体，用于治疗重度、控制不佳的哮喘。现研究人员开展随机化、双盲、平行组、安慰剂为对照的两个III期临床试验（STRATOS1和STRATOS2）评估Tralokinumab用于哮喘患者的疗效和安全性进行评估。招募12-75岁的即使应用吸入性糖皮质激素（氟替卡松或等效药物 ≥500μg/天）+长效β2受体激动剂仍控制不佳的重度哮喘患者。在STRAT

Nat Commun：FUT2-ABO上位效应提高了早期儿童哮喘和肺炎链球菌感染的呼吸系统疾病的发病风险

重度哮喘病是幼儿住院的最常见原因，其对于生活质量和医疗保健费用有着严重的影响。急性哮喘发作通常是由呼吸道感染引起的，但是导致某些儿童反复感染和急性发作的宿主因素仍未完全清楚。由于当前的治疗选择和预防措

拓展阅读

Ann Med：美泊利单抗长期安全性研究：重度哮喘患者10年随访数据

美泊利单抗在重度哮喘患者中的安全性与既往研究一致，未发现新的安全性信号。

重视嗜酸性粒细胞指标，抓住八成重度哮喘“元凶”

最新的重度哮喘防治知识和研究成果，强调嗜酸性粒细胞在重度哮喘发病中的关键作用，并呼吁哮喘患者重视嗜酸性粒细胞的检查，以助力患者更好地控制病情，告别“失控”的生活。

Nat Commun：FUT2-ABO上位效应提高了早期儿童哮喘和肺炎链球菌感染的呼吸系统疾病的发病风险

重度哮喘病是幼儿住院的最常见原因，其对于生活质量和医疗保健费用有着严重的影响。急性哮喘发作通常是由呼吸道感染引起的，但是导致某些儿童反复感染和急性发作的宿主因素仍未完全清楚。由于当前的治疗选择和预防措

Lancet respir med：临床3期试验：Tralokinumab，抗白介素13单克隆抗体，用于重度哮喘发作的效果和安全性评估

Tralokinumab，抗白介素-13的人类单克隆抗体，用于治疗重度、控制不佳的哮喘。现研究人员开展随机化、双盲、平行组、安慰剂为对照的两个III期临床试验（STRATOS1和STRATOS2）评估Tralokinumab用于哮喘患者的疗效和安全性进行评估。招募12-75岁的即使应用吸入性糖皮质激素（氟替卡松或等效药物 ≥500μg/天）+长效β2受体激动剂仍控制不佳的重度哮喘患者。在STRAT

Clin Exp Allergy：重度哮喘患者对口服泼尼松龙的反应与皮质类固醇程度有关！

由此可见，疾病严重程度并不影响全身性皮质类固醇治疗的反应。因此，这项研究并不支持重度哮喘与皮质类固醇抵抗相关的概念。只有基础嗜酸性粒细胞炎症与皮质类固醇的生理反应相关，其证实了在指导皮质类固醇治疗上测量嗜酸性粒细胞炎症的重要性。

重度哮喘的定义、评估和治疗

5月6日，我们迎来了第16个“世界哮喘日（WorldAsthmaDay，WAD）”，今年的WAD依然沿用“你可以控制你的哮喘（YouCanControlYourAsthma）”这一主题，强调了对哮喘的正确认识与积极管理。适逢欧洲呼吸学会（ERS）和美国胸科学会（ATS）联合制订的重度哮喘国际指南近期于《欧洲呼吸病学杂志》发表，下面由首都医科大学附属北京同仁医院孙永昌教授简要介绍指南内容。 定